Neuronetics Appoints Proven MedTech Leader Daniel Reuvers as CEO, Reports Strong Q4 & FY25 Results, and Issues Positive FY26 Guidance
STIM sits 27% above its 52-week low of $1.17.
Summary
Neuronetics appointed Daniel L. Reuvers, a seasoned medical technology executive, as its new CEO, while reporting strong Q4 and full year 2025 financial results, including positive Q4 operating cash flow, and issuing positive revenue guidance for 2026.
Key Events · Executive and Board Changes · STIM
-
New CEO Appointed
Daniel L. Reuvers, a healthcare executive with over 35 years of experience, including as CEO of Tactile Medical, was appointed President and CEO, effective March 23, 2026. He succeeds Keith Sullivan, who will retire.
-
Strong Q4 and Full Year 2025 Financial Results
Q4 2025 total revenue increased 86% to $41.8 million, and full year 2025 revenue grew 99% to $149.2 million. Net loss improved to $(7.2) million in Q4 2025 and $(39.1) million for the full year.
-
Positive Q4 Operating Cash Flow and Increased Cash Balance
The company generated $0.9 million in cash from operations in Q4 2025 and ended the year with $34.1 million in total cash, up from $19.5 million at the end of 2024.
-
FY 2026 Revenue Guidance Issued
Neuronetics expects full year 2026 total revenue to be between $160 million and $166 million, indicating continued growth.
Analysis · STIM · Industrial Applications And Services
Neuronetics announced the appointment of Daniel L. Reuvers as its new President and CEO, effective March 23, 2026. Mr. Reuvers brings a strong track record of growing revenue, earnings, and cash flow from his previous role as CEO of Tactile Medical, which is a significant positive for the company's strategic direction. This leadership change coincides with the release of strong financial results for Q4 and full year 2025, showing substantial revenue growth and improved net losses. Notably, the company achieved positive operating cash flow in Q4 2025 and significantly increased its cash balance. The provided 2026 guidance projects continued revenue growth, reinforcing a positive outlook. Additionally, the company amended its debt agreement, reducing obligations and interest expense, further strengthening its financial position.
At the time of this filing, STIM was trading at $1.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $93.1M. The 52-week trading range was $1.17 to $5.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.